EP365: Talking All Things Risk - Primary, Secondary, Continuum and Residual

Welcome to my podcast. I am Doctor Warrick Bishop, and I want to help you to live as well as possible for as long as possible. I’m a practising cardiologist, best-selling author, keynote speaker, and the creator of The Healthy Heart Network. I have over 20 years as a specialist cardiologist and a private practice of over 10,000 patients. Episode Summary Introduction Dr. Warwick Bishop, a physician with nearly two decades of experience in cardiovascular health, hosts this episode to demystify risk assessment and cholesterol management. The episode explores why lowering cholesterol is emphasized in cardiovascular disease prevention, addressing common misconceptions held by cholesterol skeptics through a pragmatic, evidence-based approach. Dr. Bishop discusses risk across the spectrum of primary prevention, secondary prevention, and the continuum in between, while introducing the concept of residual risk that remains even after cholesterol reduction. Key Takeaways: Secondary prevention (treating patients who have already experienced cardiac events like heart attacks or strokes) has clear evidence of benefit from cholesterol lowering, with no ambiguity about the need for treatment. Primary prevention is more complex because it involves treating heterogeneous populations where some individuals carry high-risk plaques while others don't, potentially treating many to benefit a few. Atherosclerotic cardiovascular disease should be understood as a continuum rather than a binary condition, with imaging techniques enabling early detection of plaque buildup before symptoms appear. One millimole of cholesterol reduction equates to approximately a 20% relative risk reduction of future cardiovascular events, making LDL cholesterol management a significant modifiable risk factor. Residual risk—the remaining cardiovascular risk even after substantial cholesterol lowering—is addressed through managing hypertension, smoking cessation, weight management, diet, exercise, depression, medication adherence, inflammation, clotting factors, diabetes, and triglycerides. LDL cholesterol represents approximately 50% of modifiable cardiovascular risk factors, comparable to how central banks use interest rates as a single powerful lever to influence complex economies. Lipoprotein(a) is an emerging residual risk factor with promising research expected in 2024 that may lead to new treatment approaches beyond standard LDL lowering. In primary prevention, combining traditional risk factor assessment (age, blood pressure, cholesterol, smoking, diabetes) with imaging findings creates a more accurate risk profile than either measure alone. Risk management involves identifying the "weakest link" in an individual's health chain and developing targeted intervention plans rather than applying uniform treatments. Long-term lifetime cardiovascular risk (20-50 years) should be considered rather than focusing solely on five-year risk assessments, justifying early intervention for elevated traditional risk factors even without current imaging evidence of plaque.